BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

6:06 PM
 | 
Sep 04, 2007
 |  BC Extra  |  Company News

Tibotec returns MIV-210 rights to MVIR B

Tibotec returned to Medivir (SSE:MVIR B) rights to MIV-210 for HIV and HBV following a review of its pipeline. Last June, Tibotec, which is a unit of Johnson and Johnson (JNJ), gained worldwide rights to the nucleoside...

Read the full 183 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >